CSL222 (Adeno-associated viral vector serotype 5 [AAV5]-hFIXco-Padua) for hemophilia b

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 23 Jul 2025: Trial registered, NCT07080905
  2. 28 Jul 2025: Trial started, NCT07080905

The trials

NCT07080905: Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B

State
Under way
Phase
Phase 3
People
20 planned
Started
28 Jul 2025
Primary completion
24 Oct 2033
Arms
CSL222
Results
None posted
  1. 23 Jul 2025: Trial registered
  2. 28 Jul 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Gene therapy.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.